Converting cyclosporine A from intravenous to oral administration in hematopoietic stem cell transplant recipients and the role of azole antifungals

Beauchesne PR, Chung NS, Wasan KM (2007) Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm 33(3):211–220. https://doi.org/10.1080/03639040601155665

Thomson AW (1983) Immunobiology of cyclosporin A—a review. Aust J Exp Biol Med Sci 61(Pt 2):147–172

Duncan N, Craddock C (2006) Optimizing the use of cyclosporin in allogeneic stem cell transplantation. Bone Marrow Transplant 38(3):169–174. https://doi.org/10.1038/sj.bmt.1705404

Ruutu T, Niederwieser D, Gratwohl A, Apperley JF (1997) A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 19(8):759–764. https://doi.org/10.1038/sj.bmt.1700745

Schultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ, Strong DK, Keown PA (2000) Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. Bone Marrow Transplant 26(5):545–551. https://doi.org/10.1038/sj.bmt.1702545

Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R (1991) Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7(6):461–465

Lindholm A (1991) Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13(6):465–477

Capone D, De Marino V, Fontana R, Notaro R, De Marino V, Pisanti N (1997) Effects of different routes of cyclosporin A administration on blood levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 19(4):369–372. https://doi.org/10.1038/sj.bmt.1700660

Choi JS, Lee SH, Chung SJ, Yoo KH, Sung KW, Koo HH (2006) Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 38(1):29–35. https://doi.org/10.1038/sj.bmt.1705402

McGuire T, Honaker M, Lynch J, Tarantolo S, Bishop M, Ketcham M, Pavletic S (1999) Renal dysfunction associated with cyclosporine (CSA) prophylaxis in HLA matched sibling peripheral blood stem cell transplantation (AlloBSCT): conversion from intravenous csa to a new oral formulation (Neoral). In: Blooded. Amer Soc Hematology 1200 19TH ST, NW, STE 300, WASHINGTON, DC 20036–2422 USA, pp334A-334A

Parquet N, Reigneau O, Humbert H, Guignard M, Ribaud P, Socie G, Devergie A, Esperou H, Gluckman E (2000) New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 25(9):965–968. https://doi.org/10.1038/sj.bmt.1702375

Inoue Y, Saito T, Ogawa K, Nishio Y, Kosugi S, Suzuki Y, Kato M, Sakai H, Takahashi M, Miura I (2014) Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. Am J Ther 21(5):377–384. https://doi.org/10.1097/MJT.0b013e318256ed25

Kimura S, Oshima K, Okuda S, Sato K, Sato M, Terasako K, Nakasone H, Kako S, Yamazaki R, Tanaka Y, Tanihara A, Higuchi T, Nishida J, Kanda Y (2010) Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 45(6):1088–1094. https://doi.org/10.1038/bmt.2009.316

Atiq F, Broers AE, Andrews LM, Doorduijn JK, Koch BC, Van Gelder T, Versmissen J (2016) A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. Eur J Clin Pharmacol 72(6):719–723. https://doi.org/10.1007/s00228-016-2038-9

Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48(10):1441–1458. https://doi.org/10.1086/598327

Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4(5):247–259

Niwa T, Imagawa Y, Yamazaki H (2014) Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab 15(7):651–679